VYNE Therapeutics Inc. (VYNE)
VYNE Stock Price Chart
Explore VYNE Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze VYNE price movements and trends.
VYNE Company Profile
Discover essential business fundamentals and corporate details for VYNE Therapeutics Inc. (VYNE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jan 2018
Employees
13.00
Website
https://www.vynetherapeutics.comCEO
David T. Domzalski
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
VYNE Financial Timeline
Browse a chronological timeline of VYNE Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.19.
Earnings released on 14 Aug 2025
EPS came in at -$0.13 surpassing the estimated -$0.23 by +43.48%, while revenue for the quarter reached $69.00K , missing expectations by -31.00%.
Earnings released on 8 May 2025
EPS came in at -$0.20 surpassing the estimated -$0.29 by +31.03%, while revenue for the quarter reached $202.00K , beating expectations by +304.00%.
Earnings released on 6 Mar 2025
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $84.00K , missing expectations by -16.00%.
Earnings released on 7 Nov 2024
EPS came in at -$0.29 falling short of the estimated -$0.24 by -20.83%, while revenue for the quarter reached $121.00K , missing expectations by -13.57%.
Earnings released on 14 Aug 2024
EPS came in at -$0.22 falling short of the estimated -$0.19 by -15.79%, while revenue for the quarter reached $198.00K , beating expectations by +80.00%.
Earnings released on 9 May 2024
EPS came in at -$0.15 surpassing the estimated -$0.24 by +37.50%, while revenue for the quarter reached $98.00K , missing expectations by -10.91%.
Earnings released on 29 Feb 2024
EPS came in at -$0.20 surpassing the estimated -$0.50 by +60.00%, while revenue for the quarter reached $76.00K , missing expectations by -49.33%.
Earnings released on 13 Nov 2023
EPS came in at -$1.85 falling short of the estimated -$0.76 by -143.42%, while revenue for the quarter reached $114.00K , missing expectations by -24.00%.
Earnings released on 14 Aug 2023
EPS came in at -$3.08 falling short of the estimated -$1.99 by -54.77%, while revenue for the quarter reached $135.00K , beating expectations by +35.00%.
Earnings released on 11 May 2023
EPS came in at -$1.74 surpassing the estimated -$2.50 by +30.40%, while revenue for the quarter reached $99.00K .
Earnings released on 9 Mar 2023
EPS came in at -$2.60 surpassing the estimated -$3.24 by +19.75%, while revenue for the quarter reached $6.00K , missing expectations by -90.00%.
Stock split effective on 13 Feb 2023
Shares were split 1 : 18 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at -$2.88 matching the estimated -$2.88, while revenue for the quarter reached $167.00K , beating expectations by +234.00%.
Earnings released on 12 Aug 2022
EPS came in at -$2.34 surpassing the estimated -$2.70 by +13.33%, while revenue for the quarter reached $126.00K , beating expectations by +26.00%.
Earnings released on 12 May 2022
EPS came in at -$2.52 surpassing the estimated -$2.70 by +6.67%, while revenue for the quarter reached $178.00K , missing expectations by -51.45%.
Earnings released on 17 Mar 2022
EPS came in at -$3.60 surpassing the estimated -$4.68 by +23.08%, while revenue for the quarter reached $2.29M , missing expectations by -42.99%.
Earnings released on 10 Nov 2021
EPS came in at -$6.47 falling short of the estimated -$6.12 by -5.72%, while revenue for the quarter reached $4.09M , beating expectations by +32.00%.
Earnings released on 12 Aug 2021
EPS came in at -$6.29 matching the estimated -$6.29, while revenue for the quarter reached $4.26M , missing expectations by -43.45%.
Earnings released on 6 May 2021
EPS came in at -$6.65 surpassing the estimated -$7.19 by +7.51%, while revenue for the quarter reached $4.12M , missing expectations by -8.89%.
Earnings released on 4 Mar 2021
EPS came in at -$7.73 surpassing the estimated -$8.99 by +14.02%, while revenue for the quarter reached $4.29M .
Stock split effective on 16 Feb 2021
Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 5 Nov 2020
EPS came in at -$9.35 surpassing the estimated -$12.23 by +23.55%, while revenue for the quarter reached $3.27M , missing expectations by -76.73%.
VYNE Stock Performance
Access detailed VYNE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.